Squamous Cell Carcinoma of the Skin Clinical Trial
Official title:
A Pilot Study of Neoadjuvant Cetuximab in Advanced Squamous Cell Carcinomas of Skin (SCCS)
This pilot clinical trial studies the side effects and how well cetuximab before surgery works in treating patients with skin cancer that forms, grows, and spreads quickly and has spread from where it started to nearby tissue or lymph nodes. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways be targeting certain cells. Giving cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PRIMARY OBJECTIVES: I. To assess the response rate of cetuximab by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in patients with advanced squamous cell carcinoma of skin (SCCS). II. To assess whether neoadjuvant cetuximab given in this patient population is both safe and feasible. SECONDARY OBJECTIVES: I. To measure the progression free and overall survival of patients with advanced SCCS who receive neoadjuvant cetuximab. II. To determine the conversion to resectability of patients treated with neoadjuvant cetuximab and capture changes in reconstructive options rendered possible by neoadjuvant treatment. III. Analyze the relationship of known deoxyribonucleic acid (DNA) mutations in tumor per the FoundationOneTM genomic profile, and correlate to clinical endpoints such as clinical benefit and conversion to resectability to discover potential markers of response and/or resistance. IV. Measure the downstream activation of signaling pathways without a known driver, including the epidermal growth factor receptor (EGFR) pathway. V. Determine if tumor shrinkage with cetuximab is associated with increased apoptosis as evidenced by activated caspase-3, in pre- and post- treatment tumor tissues. VI. Determine whether cetuximab results in increased antibody-dependent cell cytotoxicity (ADCC) in post-, compared with pre-treatment tumor tissues. OUTLINE: Patients receive cetuximab intravenously (IV) over 60-120 minutes once weekly for 8 weeks. After completion of study treatment, patients are followed up every 3 months for 2 years. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Active, not recruiting |
NCT06327971 -
Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
|
||
Not yet recruiting |
NCT03621462 -
Elucid Labs AIDA™ - Labelled Image Acquisition Protocol
|
N/A | |
Not yet recruiting |
NCT04480645 -
CivaDerm(TM) Surface Therapy Pilot Study
|
Early Phase 1 | |
Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
Recruiting |
NCT06014086 -
Intratumoral PH-762 for Cutaneous Carcinoma
|
Phase 1 | |
Completed |
NCT02347813 -
Preventing Squamous Cell Skin Cancer
|
Phase 2 | |
Terminated |
NCT01984892 -
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
|
Phase 2 | |
Completed |
NCT00563290 -
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT04204837 -
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
Completed |
NCT03894618 -
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Terminated |
NCT01823679 -
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
Completed |
NCT00126555 -
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
|
Phase 2 | |
Completed |
NCT00089180 -
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
|
Phase 2 | |
Not yet recruiting |
NCT05246228 -
Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
|
||
Recruiting |
NCT05886140 -
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
|
N/A | |
Recruiting |
NCT02717936 -
Investigation of Desmoplastic Squamous Cell Carcinoma
|
N/A | |
Recruiting |
NCT05482880 -
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
|
||
Withdrawn |
NCT01465815 -
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05490485 -
Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 2 |